☆ 4.8 Article

Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study

FRONTIERS IN IMMUNOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Editorial Material Gastroenterology & Hepatology

Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/ Bevacizumab

Yeonjung Ha et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

添加到收藏夹

Article Oncology

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial

Qin Xu et al.

Summary: This study investigated the efficacy and safety of sintilimab plus anlotinib as second-line or later therapy for PD-L1-positive advanced cervical cancer patients. The results showed a high objective response rate and disease control rate of sintilimab plus anlotinib in these patients, along with a certain proportion of treatment-related adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma

Jaekyung Cheon et al.

Summary: This study aimed to investigate the safety and efficacy of Atezolizumab plus bevacizumab in real settings for patients with advanced hepatocellular carcinoma. The results showed that Ate/Bev demonstrated real-life efficacy and safety in Korean patients, consistent with the phase III trial results, but showed unfavorable outcomes in patients with elevated NLR.

LIVER INTERNATIONAL (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Sorafenib Plus Hepatic ArterialInfusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized TriaL

Kanglian Zheng et al.

Summary: This study compared the efficacy and safety of sorafenib plus 3cir-OFF hepatic arterial infusion chemotherapy (HAIC) with sorafenib alone for advanced hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (PVTT). The results showed that sorafenib plus HAIC achieved better overall survival (OS) and longer progression-free survival (PFS) compared to sorafenib alone, but also had more adverse events.

RADIOLOGY (2022)

添加到收藏夹

Article Oncology

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma

Gohar Shahwar Manzar et al.

Summary: This study reports the first experience of combined radiation therapy and modern systemic therapy for hepatocellular carcinoma (HCC). The combination therapy is safe and well-tolerated, with a faster recovery of absolute lymphocyte counts (ALCs) compared to other treatment regimens, which may serve as a favorable prognosticator.

CANCERS (2022)

添加到收藏夹

Review Oncology

Radiotherapy-Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?

Erminia Romano et al.

Summary: Radiotherapy (RT) is highly effective at killing tumor cells and has additional immunomodulatory properties that can potentially improve its efficacy and cancer outcomes when combined with immunotherapy. Combining RT with immunomodulatory agents aims to enhance anti-tumor immune responses and improve treatment responses and patient outcomes. Important questions need to be addressed for effective clinical translation of RT and immunotherapy combinations, including optimal RT dose, target volume, choice of immuno-oncology agents, administration routes, and schedules.

CANCERS (2021)

添加到收藏夹

Letter Oncology

Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy

Oliver Klein et al.

CANCER CELL (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis

Li-Qing Li et al.

Summary: This study compared the long-term outcomes of robotic stereotactic body radiotherapy (SBRT) with intensity-modulated radiotherapy (IMRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). The results showed no significant difference in overall survival, progression-free survival, intrahepatic control, and local control between SBRT and IMRT groups. SBRT may be a safe and more time-efficient treatment for local advanced HCC with PVTT when high-precision tracking technology is available.

HEPATOLOGY INTERNATIONAL (2021)

添加到收藏夹

Article Oncology

Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Munire Abulimiti et al.

Summary: The study compared the outcomes of hepatocellular carcinoma (HCC) patients with portal vein thrombosis (PVTT) receiving intensity-modulated radiotherapy (IMRT) concurrent with sorafenib versus IMRT alone. Results showed that the combination therapy group had significantly better overall survival (OS), progression-free survival (PFS), and median distant metastasis-free survival (DMFS) compared to the IMRT alone group.

JOURNAL OF ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus

Wan Yee Lau et al.

Summary: A new staging system for hepatocellular carcinoma (HCC) associated with portal vein tumor thrombus (PVTT) was developed, incorporating various factors and showing good discriminatory ability to separate patients into different stages and substages.

HEPATOBILIARY SURGERY AND NUTRITION (2021)

添加到收藏夹

Meeting Abstract Oncology

IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.

Valeriy Vladimirovich Breder et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Peter R. Galle et al.

Summary: The study evaluated patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma. Results showed clinically meaningful benefits in terms of patient-reported quality of life, functioning, and disease symptoms with atezolizumab plus bevacizumab compared with sorafenib.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Evaluation of the Efficacy and Toxicity of Radiotherapy for Type III-IV Portal Vein Tumor Thrombi

Shuheng Bai et al.

Summary: Radiotherapy can effectively downstage type III and IV PVTT to type I and II, providing the opportunity for surgery. The use of image fusion technology and strict dose limitation contributes to improved radiotherapy efficiency and significant reduction in adverse complications.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2021)

添加到收藏夹

Article Oncology

Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition)

Shuqun Cheng et al.

LIVER CANCER (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Jian Zhou et al.

LIVER CANCER (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Burden of liver diseases in the world

Sumeet K. Asrani et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Article Oncology

Hepatobiliary Cancers, Version 2.2019 Featured Updates to the NCCN Guidelines

Al B. Benson et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)

添加到收藏夹

Article Oncology

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion A Randomized Clinical Trial

MinKe He et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Tumor Microenvironment as A Game Changer in Cancer Radiotherapy

Magdalena Jarosz-Biej et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Article Oncology

Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study

Xubiao Wei et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west

Jian Lu et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹

Article Oncology

Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion A Randomized Clinical Trial

Sang Min Yoon et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells

F. Faiao-Flores et al.

ONCOGENE (2017)

添加到收藏夹

Review Medicine, General & Internal

Recent Developments in Radiotherapy

Deborah E. Citrin

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma

Wei-Yao Hsieh et al.

SCIENTIFIC REPORTS (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies

Xingshun Qi et al.

PRZEGLAD GASTROENTEROLOGICZNY (2015)

添加到收藏夹

Review Surgery

The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus

Zong-ming Zhang et al.

INTERNATIONAL JOURNAL OF SURGERY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis

Takahide Nakazawa et al.

BMC GASTROENTEROLOGY (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis

Soung Won Jeong et al.

GUT AND LIVER (2013)

添加到收藏夹

Article Oncology

RADIOTHERAPY PLUS TRANSARTERIAL CHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA INVADING THE PORTAL VEIN: LONG-TERM PATIENT OUTCOMES

Sangmin Yoon et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)

添加到收藏夹

Article Oncology

Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages

Delia D'Avola et al.

ANNALS OF SURGICAL ONCOLOGY (2011)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.